-The Economic Times Should drug companies make clinical trials data public? All over the world, drug regulators are increasingly in favour of doing so, much to the discomfort of pharmaceutical companies, and the London-based European medicines Agency (EMA) is the first mover in this regard. As the journal Nature reports, EMA is likely to do so by next year, at least for some clinical trials data. On April 19, all the...

-The Hindu   "The court has recognised the right of patients to access affordable medicines over profits for big pharma companies" It was celebration time for health activists and civil society groups after the Supreme Court delivered its judgment dismissing Swiss multinational company Novartis' appeal for patent for its anti-cancer medicine imatinib mesylate or Gleevec. "We are happy that the apex court has recognised the right of patients to access affordable medicines over profits...

-The Times of India MUMBAI: Turf war between Big Pharma and generic companies, which was largely restricted to exorbitantly priced life-saving drugs for cancer and HIV, is now spilling over to other chronic ailments like diabetes, and threatening to change dynamics of the nearly Rs 70,000 crore Indian pharma market. Triggering a full-blown patent fight with US-based Merck, domestic generic company Glenmark has launched a more affordable version of the multinational's blockbuster...

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...

-Tehelka A public issue is not truly public unless Markandey Katju has passed judgement. Rahul Kotiyal and Ajachi Chakrabarti stand downwind "Journalists" writes Markandey Katju, with little sense of irony, "comment on everything under the sun." He goes on to say that when the shoe is on the other foot, when someone comments on journalism, it is misconstrued as an attack on press freedom. That when he announces he is appointing a...